1. Home
  2. JZXN vs GRI Comparison

JZXN vs GRI Comparison

Compare JZXN & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JZXN

Jiuzi Holdings Inc.

N/A

Current Price

$1.23

Market Cap

2.0M

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

N/A

Current Price

$2.94

Market Cap

1.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JZXN
GRI
Founded
2019
2018
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
1.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
JZXN
GRI
Price
$1.23
$2.94
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
2.8M
49.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.18
52 Week High
$8.50
$11.12

Technical Indicators

Market Signals
Indicator
JZXN
GRI
Relative Strength Index (RSI) 46.35 60.09
Support Level $1.20 $2.18
Resistance Level $2.00 $2.87
Average True Range (ATR) 0.20 0.19
MACD 0.00 0.00
Stochastic Oscillator 51.08 79.50

Price Performance

Historical Comparison
JZXN
GRI

About JZXN Jiuzi Holdings Inc.

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: